Veni Equities will need a jolt from either the economy or the bond market to see more trading breadth, according to Morgan Stanley strategist Mike Wilson. The “ongoing policy mix of heavy fiscal spending and tight interest rate policy is crowding out many companies and consumers in a way thatContinue Reading
TARIK KIZILKAYA Lemonade (NYSE:LMND) stock got a sorely needed boost last week when co-founder and CEO Daniel Schreiber appeared on CNBC extolling the benefits of AI in the insurance business. “Businesses within our sector that are not built on AI are missing out on one of the most forceful technologiesContinue Reading
jittawit.21 Apple will dominate how consumers use and experience AI, Wedbush tech analyst Dan Ives stressed again. Ives, an Apple (NASDAQ:AAPL) bull, tweeted Sunday “We believe the Street is starting to recognize that with Apple Intelligence on the doorstep Cupertino will be the gatekeepers of the consumer AI Revolution.” “Developers/otherContinue Reading
Dilok Klaisataporn Value stocks have continued to underperform as appetite for growth remains high. But this “underperformance should not prompt investors to stay away from all value stocks entirely … as more pointed, valuation-based strategies can still deliver favorable price returns for investors,” BMO strategist Brian Belski wrote in aContinue Reading
shapecharge Though SPDR material-focused ETF (NYSEARCA:XLB) managed to gain just 4.79% through 2024 against the broad-based index ETF (SPY) of 15.08%, almost 80% of the tickers in the sector ETF managed to peak in value over the last year. From the end of 2023 through June 20, 22 of theContinue Reading
phototechno Amylyx Pharmaceuticals (NASDAQ:AMLX) has signed an agreement with Eiger BioPharmaceuticals (OTC:EIGRQ) to acquire the rights to the latter’s Phase 3-ready GLP-1 receptor antagonist, Avexitide. Cambridge, Massachusetts-based Amylyx (AMLX) has agreed to pay $35.1M plus other payments for the acquisition, the company announced in an SEC filing late Friday. TheContinue Reading
Just_Super/E+ via Getty Images HashiCorp (NASDAQ:HCP) ticked up by 0.4% at least partly amid a report about the antitrust review of its planned sale to IBM (NYSE:IBM). The Dept. of Justice, which has a history of reviewing IBM (IBM) deals, didn’t have any issues with the $6.4 billion sale ofContinue Reading
hapabapa The U.S. Food and Drug Administration (FDA) on Friday greenlighted Bristol Myers Squibb’s (NYSE:BMY) marketing application to expand the label for its lung cancer therapy Krazati to include patients with colorectal cancer. Accordingly, Krazati, added to Bristol Myers’ (BMY) portfolio with its $4.8B Mirati acquisition this year, will beContinue Reading
hapabapa HubSpot (NYSE:HUBS) quickly gained 1% amid speculation of a third bidder for the relationship management software company. There’s speculation that a third potential acquiring is circling HubSpot, according to a Betaville “rare” alert on Friday, which cited people following the matter. HubSpot’s advisers are now trying to do aContinue Reading
U.S. stocks on Friday made small moves, amid expected volatility and uncertainty ahead of a major options expiration event. Still, Wall Street was on track for a three-week win streak. It is “triple witching” day – when stock options, stock index futures and stock index options will all expire together.Continue Reading
